TCON TRACON Pharmaceuticals Inc.

2.85
+0.1  (+4%)
Previous Close 2.75
Open 2.75
Price To Book 1.99
Market Cap 84734293
Shares 29,731,331
Volume 148,573
Short Ratio 1.38
Av. Daily Volume 152,367

SEC filingsSee all SEC filings

  1. 8-K - Current report 18902787
  2. 8-K - Current report 18896943
  3. EFFECT - Notice of Effectiveness 18851220
  4. 424B3 - Prospectus [Rule 424(b)(3)] 18850687
  5. 8-K - Current report 18850106

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiation announced December 1, 2017. Presentation of data 2H 2018.
TRC105 + Opdivo
Non-small cell lung cancer (NSCLC)
Phase 1b enrollment to be completed 2018.
TRC105 + Avastin
Non-Squamous Cell Lung Cancer
Phase 1/2 dosing commenced May 24, 2017. Completion of dose escalation phase due mid-2018.
TRC253
Prostate cancer
Phase 2 AVANTE trial initiation announced July 25, 2017.
DE-122 and Lucentis - AVANTE
Wet age-related macular degeneration (Wet-AMD)
Phase 2 dosing initiated May 2016 with poster presented January 19, 2018 at ASCO GI showing 2/8 partial responses. Enrollment to be completed by the end of 2018. Data due 1H 2019.
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2 initiated Dec 2014. Completion of enrollment announced September 7, 2017. Top-line data due 2H 2018.
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 data released February 9, 2017 - primary endpoint not met.
TRC105 and Avastin
Glioblastoma - cancer
Phase 2 trial initiated January 2016.
TRC102 and Temodar
Glioblastoma - cancer
Phase 2 initiated October 2015. Data are due in 2019.
TRC102
Mesothelioma cancer
Phase 3 dosage of first patient announced February 16, 2017. Interim analysis 2H 2018 with top-line data due 2H 2019.
TRC105 (TAPPAS)
Angiosarcoma cancer